Ann: Imugene to Present at Annual JPMorgan Healthcare Conference, page-16

I think the JP Morgan conference could be another pivotal point in Imugenes journey, mentioned in the announcement there will be a focus on azer-cel. Personally, I'm hoping for a data cut from the Vaxinia trial and also hints of efficacy from the Azer-cel trial.

Digging through old Precision slide decks it seems that a lot of their responses whether good or bad have been identified at the 28-day mark. This can be seen below in several of Precisions slides regarding their variation of trials within the azer-cel program.

https://investor.precisionbiosciences.com/static-files/df1179ae-c2c7-4f88-bb3e-431293fa6ba6

https://investor.precisionbiosciences.com/static-files/2985f288-57db-476d-ab7c-d33fecc82f57

Referring to the announcement it appears that the first patient was dosed 54 days ago on November 10^th, 2023, I’m sure the process of identifying responses is time consuming and difficult over the break but I would think by now we would be able to see initial data starting to come together. Would love to see Imugene present some clarity around the number of patients currently enrolled and some efficacy around the first patient and their progress.